Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 03 June, 2019

Winchester MD Ltd

Winchester MD appoints CFO

RNS Number : 8445A
Winchester MD Limited
03 June 2019




LONDON, 03rdJune 2019 - WINCHESTER MD LIMITED ("Winchester" or the "Company") is pleased to announce that on 28th May 2019 the Company appointed Ewan Phillips as the Chief Financial Officer of the Company.


Ewan started his career at Deloitte focusing initially on audit and subsequently corporate finance. After Deloitte he spent 17 years on the Board of Deltex Medical Group plc (LON:DEMG) - an innovative UK Life Sciences company, where, as CFO, he led the company to an IPO on AIM gaining valuable exposure to raising capital, investor relations, corporate governance and scaling the business from 15 to over 100 employees and 20x sales growth. Ewan has completed over 50 financing transactions raising over £250 million and over 50 M&A transactions with an aggregate value in excess of £1 billion. He is a Chartered Accountant.


Faz Moshfeghi, CEO and Co-founder of the Company added: "As the business of the Company continues to grow and gather momentum the management made the recent decision to find and bring on board a relevant and successful accounting professional as our CFO. In Ewan we have secured a very experienced and important member of the team to assist with our aggressive acquisition and markets strategy. He will be a valuable member of the team that adds to and complements the talents of the existing management structure that will further enable us."


For more information, please visit


On Behalf of the Board,

Faz Moshfeghi


[email protected]


About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development. 


This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.


Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.


The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t